Lactococcus lactis, a probiotic bacterium of food origin, has recently been demonstrated as a suitable strain for the production and in vivo delivery of therapeutically important proteins into the gut. We aimed to engineer recombinant L. lactis cells producing/secreting REX binding proteins that have been described as IL-23 receptor (IL-23R) blockers and IL-23R antagonists suppressing the secretion of cytokine IL-17A, a pivotal step in the T-helper Th17-mediated pro-inflammatory cascade, as well as in the development of autoimmune diseases, including inflammatory bowel disease (IBD). To reach this goal, we introduced cDNA sequences coding for REX009, REX115, and REX125 proteins into plasmid vectors carrying a Usp45 secretion signal, a FLAG tag sequence consensus, and a LysM-containing cA surface anchor (AcmA), thus allowing cell-surface peptidoglycan anchoring. These plasmids, or their non-FLAG/non-AcmA versions, were introduced into L. lactis host cells, thus generating unique recombinant L. lactis-REX strains. We demonstrate that all three REX proteins are expressed in L. lactis cells and are efficiently displayed on the bacterial surface, as tested by flow cytometry using an anti-FLAG antibody conjugate. Upon 10-fold concentration of the conditioned media, a REX125 secretory variant can be detected by Western blotting. To confirm that the FLAG/non-FLAG REX proteins displayed by L. lactis retain their binding specificity, cell-surface interactions of REX proteins with an IL-23R-IgG chimera were demonstrated by flow cytometry. In addition, statistically significant binding of secreted REX009 and REX115 proteins to bacterially produced, soluble human IL-23R was confirmed by ELISA. We conclude that REX-secreting L. lactis strains were engineered that might serve as IL-23/IL-23R blockers in an experimentally induced mouse model of colitis.

Department of Biotechnology Jožef Stefan Institute Jamova 39 SI 1000 Ljubljana Slovenia

Faculty of Pharmacy University of Ljubljana Aškerčeva 7 SI 1000 Ljubljana Slovenia

Laboratory of Ligand Engineering Institute of Biotechnology of the Czech Academy of Sciences v v i BIOCEV Research Center Průmyslová 595 252 50 Vestec Czech Republic

Laboratory of Structural Bioinformatics of Proteins Institute of Biotechnology of the Czech Academy of Sciences v v i BIOCEV Research Center Průmyslová 595 252 50 Vestec Czech Republic

Zobrazit více v PubMed

Catana C.S., Berindan Neagoe I., Cozma V., Magdas C., Tabaran F., Dumitrascu D.L. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2015;21:5823–5830. PubMed PMC

Himmel M.E., Hardenberg G., Piccirillo C.A., Steiner T.S., Levings M.K. The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology. 2008;125:145–153. doi: 10.1111/j.1365-2567.2008.02939.x. PubMed DOI PMC

Abraham C., Dulai P.S., Vermeire S., Sandborn W.J. Lessons Learned From Trials Targeting Cytokine Pathways in Patients with Inflammatory Bowel Diseases. Gastroenterology. 2017;152:374–388.e4. doi: 10.1053/j.gastro.2016.10.018. PubMed DOI PMC

Floss D.M., Schroder J., Franke M., Scheller J. Insights into IL-23 biology: From structure to function. Cytokine Growth Factor Rev. 2015;26:569–578. PubMed

Duijvestein M., Battat R., Vande Casteele N., D’Haens G.R., Sandborn W.J., Khanna R., Jairath V., Feagan B.G. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr. Treat. Options Gastroenterol. 2018;16:129–146. doi: 10.1007/s11938-018-0175-1. PubMed DOI

Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R., Blank M.A., Johanns J., Gao L.L., Miao Y., et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N. Engl. J. Med. 2016;375:1946–1960. doi: 10.1056/NEJMoa1602773. PubMed DOI

Quiniou C., Dominguez-Punaro M., Cloutier F., Erfani A., Ennaciri J., Sivanesan D., Sanchez M., Chognard G., Hou X., Rivera J.C., et al. Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014;307:R1216–R1230. doi: 10.1152/ajpregu.00540.2013. PubMed DOI

Kretz-Rommel A., Wild M., Bowdish K., Chen E., Oltean D., Gonzalez M., Kapoor M. Polypeptides that bind IL-23R. 2011/043835 A1. Patent WO. 2010 Apr 14

Kuchar M., Vankova L., Petrokova H., Cerny J., Osicka R., Pelak O., Sipova H., Schneider B., Homola J., Sebo P., et al. Human interleukin-23 receptor antagonists derived from an albumin-binding domain scaffold inhibit IL-23-dependent ex vivo expansion of IL-17-producing T-cells. Proteins. 2014;82:975–989. doi: 10.1002/prot.24472. PubMed DOI PMC

Skrlec K., Strukelj B., Berlec A. Non-immunoglobulin scaffolds: A focus on their targets. Trends Biotechnol. 2015;33:408–418. doi: 10.1016/j.tibtech.2015.03.012. PubMed DOI

Hlavnickova M., Kuchar M., Osicka R., Vankova L., Petrokova H., Maly M., Cerny J., Arenberger P., Maly P. ABD-Derived Protein Blockers of Human IL-17 Receptor A as Non-IgG Alternatives for Modulation of IL-17-Dependent Pro-Inflammatory Axis. Int. J. Mol. Sci. 2018;19:E3089. doi: 10.3390/ijms19103089. PubMed DOI PMC

Krizova L., Kuchar M., Petrokova H., Osicka R., Hlavnickova M., Pelak O., Cerny J., Kalina T., Maly P. p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells. Autoimmunity. 2017;50:102–113. doi: 10.1080/08916934.2016.1272598. PubMed DOI

Mareckova L., Petrokova H., Osicka R., Kuchar M., Maly P. Novel binders derived from an albumin-binding domain scaffold targeting human prostate secretory protein 94 (PSP94) Protein Cell. 2015;6:774–779. doi: 10.1007/s13238-015-0194-9. PubMed DOI PMC

Zadravec P., Mareckova L., Petrokova H., Hodnik V., Perisic Nanut M., Anderluh G., Strukelj B., Maly P., Berlec A. Development of Recombinant Lactococcus lactis Displaying Albumin-Binding Domain Variants against Shiga Toxin 1 B Subunit. PLoS ONE. 2016;11:e0162625. doi: 10.1371/journal.pone.0162625. PubMed DOI PMC

Ahmad J.N., Li J., Biedermannova L., Kuchar M., Sipova H., Semeradtova A., Cerny J., Petrokova H., Mikulecky P., Polinek J., et al. Novel high-affinity binders of human interferon gamma derived from albumin-binding domain of protein G. Proteins. 2012;80:774–789. doi: 10.1002/prot.23234. PubMed DOI

Douillard F., de Vos W.M. Functional genomics of lactic acid bacteria: From food to health. Microb. Cell Fact. 2014:13. doi: 10.1186/1475-2859-13-S1-S8. PubMed DOI PMC

Sanders M.E. Probiotics: Definition, sources, selection, and uses. Clin. Infect. Dis. 2008;46(Suppl 2):S58–S61. doi: 10.1086/523341. discussion S144–S151. PubMed DOI

Plavec T.V., Berlec A. Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides. Appl. Microbiol. Biotechnol. 2019;103:2053–2066. doi: 10.1007/s00253-019-09628-y. PubMed DOI

Ravnikar M., Strukelj B., Obermajer N., Lunder M., Berlec A. Engineered lactic acid bacterium Lactococcus lactis capable of binding antibodies and tumor necrosis factor alpha. Appl. Env. Microbiol. 2010;76:6928–6932. doi: 10.1128/AEM.00190-10. PubMed DOI PMC

Berlec A., Perse M., Ravnikar M., Lunder M., Erman A., Cerar A., Strukelj B. Dextran sulphate sodium colitis in C57BL/6J mice is alleviated by Lactococcus lactis and worsened by the neutralization of Tumor necrosis Factor alpha. Int. Immunopharmacol. 2017;43:219–226. doi: 10.1016/j.intimp.2016.12.027. PubMed DOI

Simcic S., Berlec A., Stopinsek S., Strukelj B., Orel R. Engineered and wild-type L. lactis promote anti-inflammatory cytokine signalling in inflammatory bowel disease patient’s mucosa. World J. Microbiol. Biotechnol. 2019;35:45. doi: 10.1007/s11274-019-2615-z. PubMed DOI

Holo H., Nes I.F. Transformation of Lactococcus by electroporation. Methods Mol. Biol. 1995;47:195–199. PubMed

Mierau I., Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in Lactococcus lactis. Appl. Microbiol. Biotechnol. 2005;68:705–717. doi: 10.1007/s00253-005-0107-6. PubMed DOI

Skrlec K., Pucer Janez A., Rogelj B., Strukelj B., Berlec A. Evasin-displaying lactic acid bacteria bind different chemokines and neutralize CXCL8 production in Caco-2 cells. Microb. Biotechnol. 2017;10:1732–1743. doi: 10.1111/1751-7915.12781. PubMed DOI PMC

Skrlec K., Zadravec P., Hlavnickova M., Kuchar M., Vankova L., Petrokova H., Krizova L., Cerny J., Berlec A., Maly P. p19-Targeting ILP Protein Blockers of IL-23/Th-17 Pro-Inflammatory Axis Displayed on Engineered Bacteria of Food Origin. Int. J. Mol. Sci. 2018;19:E1933. doi: 10.3390/ijms19071933. PubMed DOI PMC

Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol Biol. 1993;234:779–815. doi: 10.1006/jmbi.1993.1626. PubMed DOI

Webb B., Sali A. Comparative Protein Structure Modeling Using MODELLER. Curr Protoc Bioinform. 2014;47:5.6.1–5.6.30. doi: 10.1002/0471250953.bi0506s47. PubMed DOI

Johansson M.U., Frick I.M., Nilsson H., Kraulis P.J., Hober S., Jonasson P., Linhult M., Nygren P.A., Uhlen M., Bjorck L., et al. Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J. Biol. Chem. 2002;277:8114–8120. doi: 10.1074/jbc.M109943200. PubMed DOI

Bloch Y., Bouchareychas L., Merceron R., Skladanowska K., van den Bossche L., Detry S., Govindarajan S., Elewaut D., Haerynck F., Dullaers M., et al. Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rbeta1. Immunity. 2018;48:45–58.e6. doi: 10.1016/j.immuni.2017.12.008. PubMed DOI PMC

Sievers F., Wilm A., Dineen D., Gibson T.J., Karplus K., Li W.Z., Lopez R., McWilliam H., Remmert M., Soding J., et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011:7. doi: 10.1038/msb.2011.75. PubMed DOI PMC

Kozakov D., Beglov D., Bohnuud T., Mottarella S.E., Xia B., Hall D.R., Vajda S. How good is automated protein docking? Proteins. 2013;81:2159–2166. doi: 10.1002/prot.24403. PubMed DOI PMC

Kozakov D., Brenke R., Comeau S.R., Vajda S. PIPER: An FFT-based protein docking program with pairwise potentials. Proteins. 2006;65:392–406. doi: 10.1002/prot.21117. PubMed DOI

Buist G., Kok J., Leenhouts K.J., Dabrowska M., Venema G., Haandrikman A.J. Molecular cloning and nucleotide sequence of the gene encoding the major peptidoglycan hydrolase of Lactococcus lactis, a muramidase needed for cell separation. J. Bacteriol. 1995;177:1554–1563. doi: 10.1128/jb.177.6.1554-1563.1995. PubMed DOI PMC

Dieye Y., Usai S., Clier F., Gruss A., Piard J.C. Design of a protein-targeting system for lactic acid bacteria. J. Bacteriol. 2001;183:4157–4166. doi: 10.1128/JB.183.14.4157-4166.2001. PubMed DOI PMC

Zadravec P., Strukelj B., Berlec A. Improvement of LysM-mediated surface display of designed ankyrin repeat proteins (DARPins) in recombinant and nonrecombinant strains of Lactococcus lactis and Lactobacillus Species. Appl. Env. Microbiol. 2015;81:2098–2106. doi: 10.1128/AEM.03694-14. PubMed DOI PMC

Walker A.W., Sanderson J.D., Churcher C., Parkes G.C., Hudspith B.N., Rayment N., Brostoff J., Parkhill J., Dougan G., Petrovska L. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7. doi: 10.1186/1471-2180-11-7. PubMed DOI PMC

Vamanu E. Complementary Functional Strategy for Modulation of Human Gut Microbiota. Curr. Pharm. Des. 2018;24:4144–4149. doi: 10.2174/1381612824666181001154242. PubMed DOI

Sanders M.E., Guarner F., Guerrant R., Holt P.R., Quigley E.M., Sartor R.B., Sherman P.M., Mayer E.A. An update on the use and investigation of probiotics in health and disease. Gut. 2013;62:787–796. doi: 10.1136/gutjnl-2012-302504. PubMed DOI PMC

A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis